Avalo Therapeutics, Inc. reported $441K of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $441K (to Q4 2024). Net income: −$100M, trailing twelve months to Q2 2026. EPS: −$4.37, trailing twelve months to Q2 2026.

AVTXAvalo Therapeutics, Inc.

Healthcare

$13.43-0.37% 1Y

$13.43

$12.7452 weeks$22.87

AVTX as reported

Avalo Therapeutics, Inc. reported $441K of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$441K

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$100M
Net income · +117% year on year · trailing twelve months to Q2 2026
EPS: −$4.37
EPS · +2.1% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AVTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$441K	n/a	Q4 2024 · 6 quarters behind
Net income	−$100M	+117%	Q2 2026
EPS	−$4.37	+2.1%	Q2 2026
Gross margin	27%	n/a	Q4 2023 · 10 quarters behind
Operating margin	−1473%	n/a	Q4 2023 · 10 quarters behind
Net margin	−1754%	n/a	Q4 2023 · 10 quarters behind
ROE	−87%	n/a	Q2 2026
ROA	−63%	n/a	Q2 2026
ROIC	4291%	n/a	Q4 2023 · 10 quarters behind
Free cash flow	−$49M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.